A pharmaceutical compound approved 21 years ago to treat breast cancer in postmenopausal women is showing fresh promise as a therapy for glioblastomas. 

The boon comes in the form of greater brain cortical thickness observable on neonatal MRI two weeks after the baby enters the world.

Researchers found that cancer risk in premenopausal women with fatty breasts at initial imaging nearly doubled if an increase in density was observed during their second and third mammograms.

The FDA has given its thumbs-up to software that calculates breast fibroglandular tissue volume (FGV) and the ratio of FGV to total breast volume on ultrasound imaging.

Researchers in the U.K. have documented fetuses smiling when exposed to sweet flavors and frowning over bitter tastes.

Using a new 4D flow cardiac MRI scan, experts were able to complete cardiac examinations in just eight minutes.

A machine learning system has come along that needs no human labeling of data for training yet matches radiologists at classifying diseases on chest X-rays—including some that the model was not specifically taught to detect.

The Sept. 21 announcement states that Gadopiclenol Injection—a highly stable macrocyclic gadolinium-based contrast agent—is approved for use in adult and pediatric patients aged 2 years and older during MRI exams.